ACKR4P1: A Potential Drug Target and Biomarker (G285737)

Target Name: ACKR4P1

NCBI ID: G285737

ACKR4P1

Other Name(s): CCRL1P | Chemokine (C-C motif) receptor-like 1 pseudogene | CCRL1P1 | ACKR4 pseudogene 1 | dJ509I19.4

ACKR4P1: A Potential Drug Target and Biomarker

ACKR4P1 (CCRL1P), a protein located in the endoplasmic reticulum (ER), has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and subcellular localization in the ER make it an attractive target for small molecules and antibodies.

ACKR4P1 is a 21-kDa protein that is expressed in most tissues and is highly conserved across different species. It is localized to the endoplasmic reticulum, where it plays a role in the quality control of protein synthesis and degradation. The ER is a specialized organelle that functions as a transport system for importing and exporting proteins. The endoplasmic reticulum is the final destination for proteins that have been synthesized in the cytoplasm and is responsible for their folding, localization, and degradation.

ACKR4P1 is a key regulator of protein synthesis and degradation in the ER. It is involved in the regulation of protein loading into the ER and in the degradation of misfolded proteins. The most significant function of ACKR4P1 is its role in the regulation of the size and composition of the ER. It does this by interacting with multiple partner proteins, including the transmembrane protein, TIR1.

ACKR4P1 is also involved in the regulation of protein stability and dynamics. It interacts with the protein degradation machinery, including the 26S proteasome and theBeclin-1 (Bcl-1) gene. The 26S proteasome is the largest protein-protein complex in the ER that is involved in protein degradation. The Beclin-1 gene encodes a protein that is involved in the regulation of protein stability and can also interact with ACKR4P1.

ACKR4P1 is a potential drug target due to its unique structure and subcellular localization in the ER. Its location in the ER allows it to interact with a variety of partner proteins, including small molecules and antibodies. The ER is also a common site for drug discovery, as many drugs work by modulating the activity of proteins that are expressed in the ER.

ACKR4P1 is also a potential biomarker for various diseases, including cancer. Its expression is often reduced in cancer cells compared to normal cells, which makes it an attractive target for diagnostic and therapeutic applications. The expression of ACKR4P1 has also been used as a biomarker for various neurological and psychiatric diseases, including Alzheimer's disease and depression.

In conclusion, ACKR4P1 is a protein that is located in the endoplasmic reticulum and plays a critical role in the regulation of protein synthesis and degradation in the ER. Its unique structure and subcellular localization make it an attractive target for small molecules and antibodies, and its involvement in the regulation of protein stability and dynamics make it a potential drug target and biomarker for various diseases. Further research is needed to fully understand the functions of ACKR4P1 and its potential as a drug target and biomarker.

Protein Name: ACKR4 Pseudogene 1

The "ACKR4P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACKR4P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets